Kari Hacker, MD
Gynecologic Oncology · Raleigh, NCNPI 1649561457
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by GSK at 27.8% of the total. Reporting peaked in 2024 at $375 and has fallen 79.6% since, to $77 in 2025. That places this record below the midpoint for gynecologic oncology clinicians in NC, where the typical reported total is $1,376.
Across 35 payments — averaging $30.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$294
- AstraZeneca$253
- Davol Inc.$155
- Eisai Inc.$73
- Merck$73
- AbbVie$63
- plus $145 from 4 others
Across 20 payments — averaging $3910.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$78K
What the payments were for
- Food & beverage$1,054100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 11 | $294 |
| AstraZeneca | 8 | $253 |
| Davol Inc. | 1 | $155 |
| Eisai Inc. | 3 | $73 |
| Merck | 3 | $73 |
| AbbVie | 3 | $63 |
| Genmab U.S., Inc. | 2 | $59 |
| Clovis Oncology, Inc. | 2 | $45 |
| Foundation Medicine, Inc. | 1 | $24 |
| Photocure Inc | 1 | $17 |
How this compares
$1,054 in reported general payments places this provider in the 40th percentile of 52 gynecologic oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 12 | $954 |
| Megestrol Acetate | 14 | $414 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $76 |
| Duloxetine Hcl | 13 | $74 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Raleigh
- Kimberly DessourcesRaleigh$3K
- Lucybeth Nieves ArribaWilmington$251K
- Robert NaumannCharlotte$221K
- Angeles SecordDurham$121K
- Erin CraneCharlotte$98K
- Michael SundborgSouthern Pines$85K
- William LoweryDurham$67K
- Emma RossiGreensboro$62K
- Jubilee BrownCharlotte$44K
- Victoria Bae-JumpChapel Hill$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.